Cheap financings Startups, both private and public have a myriad of options when it comes to raising capital. One method that’s gained a lot of traction over the last…
Taylor Gavinchuk
Doubling down on Cybin Back in January, Horizons’ (PYSK.NE) ETF held a relatively balanced portfolio of psychedelics companies. No company made up more than 10% of its holdings, with…
Oura Rings I have an Oura Ring, I bought it a few years back to try and better understand my sleeping patterns. After a few months of use, I…
Shorter trips Remember early YouTube days when (insert activity here ______ on salvia) were some of the most popular videos on the internet? Well, it turns out salvia is…
Data protection Earlier this week a federal review echoed The Canadian Ministry of Health’s original decision to deny data protection for Johnson & Johnson (JNJ.Q)’s Spravato product, a ketamine-derived…
Death & children’s novels When I think about Amanita Muscaria the first two things that come to mind are death, and children’s novels. Amanita Muscaria is arguably the…
90% There are a lot of newer investors interested in psychedelics, which is great. But, there are some pretty big pitfalls to watch out for out there. It’s important…
Forget weed crypto First off, most all of those crypto/cannabis hybrid deals were super cringe, and I never saw the point of combining the two, at least not at…
The NYSE Cybin (CYBN.N) just finished its first trading day on the New York Stock Exchange (NYSE) after announcing the upcoming uplisting last month. It was a less…
MAPS, FDA & Health Canada In a highly regulated sector like psychedelics, governing bodies like the FDA and Health Canada have the power to shape and influence how an…